Serologicals (NASDAQ:SERO)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Serologicals Charts. Click Here for more Serologicals Charts.](/p.php?pid=staticchart&s=N%5ESERO&p=8&t=15)
Serologicals Corporation (NASDAQ: SERO) announced today
that Chemicon International, Inc., its wholly-owned subsidiary, and
Stem Cell Sciences Holdings LTD (SCS), have signed an exclusive
agreement to manufacture and market novel patent-protected embryonic
stem (ES) cell media for the research market. Under the terms of this
agreement, SCS will transfer the patented technology and expertise to
Chemicon to allow it to manufacture a fully formulated cell culture
media that Chemicon will exclusively market worldwide.
This novel media has substantial improvements over animal-serum
based media formulations. The availability of this new serum-free,
ready-to-use media offers advantages in convenience and
reproducibility, eliminating lot-to-lot variations inherent with the
use of animal serum. Specific formulations will be provided for
different aspects of passaging and clonal selection of mammalian ES
cells. The flagship ready-to-use formulation will contain Chemicon's
proprietary LIF as well as proprietary molecules patented by SCS.
SCS has been active in the stem cell research arena since 1994,
principally focused on technologies to grow, differentiate, select and
purify embryonic stem cells. SCS has a substantial portfolio of
patents and patent applications within these areas, and intends to
develop SC-based therapies.
"Chemicon is excited to add these new ES cell culture media
formulations to our portfolio of innovative reagents and technologies
for the global stem cell research community," said Jeffrey D. Linton,
President of Chemicon. "These new media formulations will aid
researchers in the passaging and selection of mammalian ES cell lines.
These new products will broaden the solutions already being provided
to thousands of ES cell researchers worldwide via our LIF and ESGRO(R)
product lines. In addition, we look forward to furthering our
collaboration with Stem Cell Sciences to co-develop and market
additional innovative ES cell products."
"We are pleased to enter this agreement with a well-established
stem cell research solutions provider such as Chemicon," said Peter
Mountford, CEO of Stem Cell Sciences. "Chemicon is well positioned in
the stem cell arena to both manufacture and provide the serum-free,
fully formulated ES cell media formulations we have developed to
researchers in the field of stem cell research and regenerative
medicine."
Chemicon International, Inc. offers a broad range of research
products, including specialty reagents, kits, antibodies, and custom
products and services, to customers working in the areas of
neuroscience, stem cell biology, cancer, and infectious disease
research. It is also a leading supplier of monoclonal antibodies,
conjugates, antibody blends and molecular-based detection kits for use
in diagnostic laboratories. Chemicon focuses on basic and biomedical
research, drug discovery, and diagnostics, allowing it to serve
thousands of customers worldwide in the academic, clinical,
biotechnology, and pharmaceutical sectors. Acquired in 2003, Chemicon
is a Serologicals company, based in Temecula, CA.
For more information, please visit our website: www.chemicon.com
Serologicals Corporation (NASDAQ: SERO), headquartered in Atlanta,
GA., is a global leader in developing and commercializing consumable
biological products, enabling technologies and services in support of
biological research, drug discovery, and the bioprocessing of
life-enhancing products. Our customers include researchers at major
life science companies and leading research institutions involved in
key disciplines, such as neurology, oncology, hematology, immunology,
cardiology, proteomics, infectious diseases, cell signaling and stem
cell research. In addition, Serologicals is the world's leading
provider of monoclonal antibodies for the blood typing industry.
Serologicals employs a total of more than 1,000 people worldwide in
three Serologicals' companies: Chemicon International, headquartered
in Temecula, CA, Upstate Group, LLC, headquartered in Charlottesville,
VA. and Celliance Corporation, headquartered in Atlanta, GA.
For more information, please visit our website:
www.serologicals.com
About Stem Cell Sciences
Stem Cell Sciences has been a leading company in the stem cell
research arena since 1994, focused on technologies to grow,
differentiate, select and purify embryonic stem cells. The SCS group
has headquarters in Edinburgh, UK and laboratories in Melbourne,
Australia and Kobe, Japan. It is expanding operations from 2006 to
Cambridge UK and the USA. The new UK site in Cambridge will focus on
automation of cell based drug discovery assays for the pharmaceutical
industry. The US expansion will initially be based on licensing
opportunities of key SCS technologies, including Stem Cell Selection
and novel Neural Stem cells reported in August this year. Stem Cell
Sciences plc was listed on the London AIM in July 2005.
For more information, please visit our website:
www.stemcellsciences.com
This release contains certain forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995.
Words or phrases such as "should result," "are expected to," "we
anticipate," "we estimate," "we project" or similar expressions are
intended to identify forward-looking statements. These statements are
subject to certain risks and uncertainties that could cause actual
results to differ materially from those expressed in any
forward-looking statements. You should not place undue reliance on
forward-looking statements, since the statements speak only as of the
date that they are made, and the Company undertakes no obligation to
update these statements based on events that may occur after the date
of this press release.
Serologicals is a registered trademark of Serologicals Investment
Company.